{
"vaccines" : [{"id" : 0 ,
  "name" : "Inactivated Influenza (IIV)",
  "indication" : "All adults who are ≥ 65 yrs." ,
  "administration":"One <b>IIV</b> dose every year in the fall or winter" ,
  "contrain":"- Previous severe allergic reaction <br> - Moderate or severe acute illness with or without fever"
},


  {"id" : 1 ,
    "name" : "Tetanus, diphtheria, pertussis(Td:Tdap)",
    "indication" : "All people who lack written documentation of a primary series consisting of at least 3 doses of tetanus- and diphtheria-toxoid-containing vaccine" ,
    "administration":"Substitute 1-time dose of Tdap for Td booster; then boost with Td every 10 yrs" ,
    "contrain":"- Previous severe allergic reaction<br> - For Tdap only, history of encephalopathy not attributable to an identifiable cause, within 7d following DTP/DTaP, or Tdap"
  },


  {"id" : 2 ,
    "name" : "Pneumococcal conjugate (PCV13)",
    "indication" : "- All people ≥ 65 yrs.<br> Should receive 1 - time dose of PCV13 (if previously unvaccinated) and 1 dose of PPSV23" ,
    "administration":"Adults aged ≥ 65 who:<br> - Have not received PCV13 or PPSV23: Administer PCV13 followed by PPSV23 one year later unless the patient has a high-risk medical condition (such immunocompromised or asplenia), then the first PPSV23 dose can follow the PCV13 by 8 wks<br> - Have not received PCV13 but have received a dose of PPSV23 at age≥ 65: Administer PCV13  at least one year after the dose of PPSV23 received at age ≥ 65<br> - Have not received PCV13 but have received 1 or more doses of PPSV23 before age 65: Administer PCV13 at least 1 year after the most recent dose of PPSV23; administer a dose of PPSV23  at 12 months after PCV13, or as soon as possible if this time window has passed, and at least 5 years after the most recent dose of PPSV23.<br> - Have received PCV13 but not PPSV23 before age 65 years: Administer PPSV23 at 12 months after PCV13 or as soon as possible if this time window has passed.<br> - Have received PCV13 and 1 or more doses of PPSV23 before age 65 years: Administer PPSV23 at12 months after PCV13, or as soon as possible if this time window has passed, and at least 5 years after the most recent dose of PPSV23." ,
    "contrain":"- Previous severe allergic reaction to this vaccine, including (for PCV13) to any diphtheria toxoid-containing vaccine, or to any of its components<br> - Moderate or severe acute illness"
  },


  {"id" : 3 ,
    "name" : "Pneumococcal polysaccharide(PPSV23)",
    "indication" : "- No additional dose of PPSV23 is indicated for adults vaccinated with PPSV23 at or after age 65 years" ,
    "administration":"Adults aged ≥ 65 who:<br> - Have not received PCV13 or PPSV23: Administer PCV13 followed by PPSV23 one year later unless the patient has a high-risk medical condition (such immunocompromised or asplenia), then the first PPSV23 dose can follow the PCV13 by 8 wks<br> - Have not received PCV13 but have received a dose of PPSV23 at age≥ 65: Administer PCV13  at least one year after the dose of PPSV23 received at age ≥ 65<br> - Have not received PCV13 but have received 1 or more doses of PPSV23 before age 65: Administer PCV13 at least 1 year after the most recent dose of PPSV23; administer a dose of PPSV23  at 12 months after PCV13, or as soon as possible if this time window has passed, and at least 5 years after the most recent dose of PPSV23.<br> - Have received PCV13 but not PPSV23 before age 65 years: Administer PPSV23 at 12 months after PCV13 or as soon as possible if this time window has passed.<br> - Have received PCV13 and 1 or more doses of PPSV23 before age 65 years: Administer PPSV23 at12 months after PCV13, or as soon as possible if this time window has passed, and at least 5 years after the most recent dose of PPSV23." ,
    "contrain":"- Previous severe allergic reaction to this vaccine, including (for PCV13) to any diphtheria toxoid-containing vaccine, or to any of its components<br> - Moderate or severe acute illness"
  },


  {"id" : 4 ,
    "name" : "Hepatitis A (HepA) IM",
    "indication" : "All adults ≥ 65 yrs. who want to be protected from (HAV) infection if some other risk factor is present" ,
    "administration":"2 dose schedule with a minimum of 6 month interval" ,
    "contrain":" - Previous severe allergic reaction <br> - Moderate or severe acute illness"
  },


  {"id" : 5 ,
    "name" : "Hepatitis B (HepB) IM",
    "indication" : "Recommended if some other risk factor is present " ,
    "administration":"3-dose series at 0, 1 and 6 month intervals(the 2<small><sup>nd</small></sup>should be at least 4 wks after the 1<small><sup>st</small></sup> and the 3<small><sup>rd</small></sup> should be at least 8 wks after the 2<small><sup>nd</small></sup> and at least 16 wks after the 1<small><sup>st</small></sup>)" ,
    "contrain":"- Previous severe allergic reaction <br> - Moderate or severe acute illness"
  },


  {"id" : 6 ,
    "name" : "Zoster (Shingles)",
    "indication" : "Adults aged 60 years or older regardless of whether they report a prior episode of herpes zoster" ,
    "administration":"1 dose" ,
    "contrain":"- Previous severe allergic reaction <br> - Primary cellular or acquired immunodeficiency <br> - Pregnancy <br> - Receipt of specific antivirals 24hrs before vaccination<br> - Moderate or severe acute illness"
  },


  {"id" : 7 ,
    "name" : "MMR (Measles, Mumps, Rubella)",
    "indication" : "- Individuals at higher risk of either exposure or morbidity e.g., Healthcare personnel, international travelers, Household and close contacts of immunocompromised persons, HIV-infected individuals who do not have current evidence of severe immunosuppression" ,
    "administration":"- Adults with no evidence of immunity should get 1 dose of MMR unless the adult is in a high risk group.<br> - Individuals at high risk should have two doses separated by at least one month or serologic evidence of immunity." ,
    "contrain":"- Previous severe allergic reaction<br> - Pregnancy or possibility of pregnancy within 4wks<br> - Immuno-compromising conditions<br> - Severe immunodeficiency<br> - History of thrombocytopenia or thrombocytopenic purpura"
  },

  {"id" : 8 ,
    "name" : "Varicella (Chickenpox)",
    "indication" : "A person age 60 years or older who has no medical contraindications, is eligible for zoster vaccine regardless of their memory of having had chickenpox.<br> However, if an adult age 60 years or older is tested for varicella immunity for whatever reason, and the test is negative, he/she should be given 2 doses of varicella vaccine at least 4 weeks apart, not zoster vaccine." ,
    "administration":"- 2 doses <br> - Dose #2 is given 4—8 wks after dose #1.<br> - If dose #2 is delayed, do not repeat dose #1, just give dose #2." ,
    "contrain":"- Previous severe allergic reaction (e.g. anaphylaxis)<br> - Pregnancy<br> - Long-term immunosuppressive therapy or immunocompromised pts<br> - Receipt of specific antivirals<br> - Moderate or severe acute illness"
  }]
,"icon" : "sec6logo"
,"name" : "Aged People Over 65 Years"
,"ref" : "*Evidence of immunity to varicella in adults includes any of the following:<br>- Documentation of 2 doses of varicella vaccine at least 4 weeks apart<br>- History of varicella based on diagnosis or verification of varicella disease by a health care provider<br>- History of herpes zoster based on diagnosis or verification of herpes zoster disease by a health care provider <br>- Laboratory evidence of immunity or laboratory confirmation of disease.<br>1. http://www.immunize.org/askexperts/experts_zos.asp<br>2- Summary of Recommendations for Adult Immunization (Age 19 years and older). Centers for Disease Control and Prevention. 2015"
,"bg" : "sec6bg"
,"btnBg" : "sec6btnbg"
,"textColor" : "sec6color"
}
